MCM
NKTR icon

MAI Capital Management’s Nektar Therapeutics NKTR Stock Holding History

MAI Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288 Buy
+4
New +$228 ﹤0.01% 4539
2025
Q4 		– Sell
-33
Closed -$1.88K – 4439
2025
Q3 		$1.88K Buy
+33
New +$1.09K ﹤0.01% 3322

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

MAI Capital Management's NKTR Position: Q1 2026 in Review

MAI Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 4 shares worth $288. The stake represents ﹤0.01% of the portfolio and ranks #4539 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in NKTR as recently as Q3 2025.

MAI Capital Management first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.88K in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • MAI Capital Management held 4 shares of Nektar Therapeutics worth $288 as of Q1 2026.
  • Nektar Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4539 holding.
  • MAI Capital Management first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • MAI Capital Management's Nektar Therapeutics position peaked at $1.88K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.